Switzerland Archives

In Depth 17 Jan 2023

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […]

January 17, 2023 - 5 minutesmins - By External Contributor

In Depth 5 Jan 2023

Navignostics maps tumor proteomes to improve precision oncology

New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […]

January 5, 2023 - 4 minutesmins - By Jonathan Smith

More News! 21 Dec 2022

Watch: Aphaia Pharma interview

Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […]

December 21, 2022 - 1 minutemin - By Jim Cornall

News and Trends 21 Dec 2022

Watch: Araris Biotech at Bio-Europe

Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug-conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

PDCline Pharma presents first immunological results from trial with PDClung01

PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […]

December 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Dec 2022

MetrioPharm reveals COVID-19 study data

MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. In the trial, patients received either MP1032 plus standard of care (SoC), or placebo plus SoC. SoC partially included other antivirals (Remdesivir or Nirmatrelvir/Ritonavir), […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Laevoroc Oncology pushes for relapsed leukemia cure

Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […]

December 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Dec 2022

INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer

OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […]

December 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Localizing BRCA gene mutations to better treat ovarian cancer

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […]

November 28, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

FMRP – the protein behind immunotherapy resistance

Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […]

November 21, 2022 - 6 minutesmins - By Jim Cornall

Startup Scout 15 Nov 2022

Nagi Bioscience tests drugs on worms using microfluidics

The Swiss startup Nagi Bioscience aims to speed up drug and chemical safety testing by automating research on a worm called Caenorhabditis elegans. For companies developing a drug or chemical product, there are many ways to predict the safety of their compound in humans. They can test the drugs in cell cultures, which are cheap […]

November 15, 2022 - 5 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

Cell and gene therapies gain momentum in Basel

Navignostics maps tumor proteomes to improve precision oncology

Watch: Aphaia Pharma interview

Watch: Araris Biotech at Bio-Europe

PDCline Pharma presents first immunological results from trial with PDClung01

MetrioPharm reveals COVID-19 study data

Laevoroc Oncology pushes for relapsed leukemia cure

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer

Localizing BRCA gene mutations to better treat ovarian cancer

FMRP – the protein behind immunotherapy resistance

Nagi Bioscience tests drugs on worms using microfluidics

Subscribe to our newsletter to get the latest biotech news!